Prostat kanserinde Pozitron Emisyon Tomografisi/BilgisayarlıTomografi’ nin rolü

Prostat kanseri erkeklerde ikinci en sık görülen kanserdir. Evrelemede bilgisayarlı tomografi, manyetik rezonans görüntüleme, kemik sintigrafisi, Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi (PET/BT) kullanılmaktadır. PET/BT ile görüntüleme için Flor-18 Florodeoksiglukoz, kolin, asetat gibi çeşitli radyofarmasötikler kullanılmaktadır. Bu makalede prostat kanserinde PET/BT’ nin rolünün açıklanması amaçlanmıştır.

The role of Positron Emission Tomography/Computed Tomography in prostate cancer

Prostate cancer is the second most common cancer in males. Computed tomography, magnetic resonance imaging,bone scan, Positron Emission Tomography/Computed Tomography (PET/CT) is used for staging. A variety ofradiopharmaceuticals such as Fluorine-18 Fluorodeoxyglucose, choline, acetate are used for PET/CT imaging. Thisarticle is aimed to describe the role of PET/CT in prostate cancer.

PDF

___

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Warburg O, Wind F, Negelein E. The metabolısm of tumors ın the body. J Gen Physiol. 1927;8:519-30.
3. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81-9.
4. Röthke MC, Afshar-Oromieh A, Schlemmer HP: Potential of PET/MRI for diagnosis of prostate cancer. Radiologe. 2013;53:676-81.
5. Lee ST, Lawrentschuk N, Scott AM. PET in prostate and bladder tumors. Semin Nucl Med. 2012;42:231-46.
6. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-92.
7. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med. 2011;41:29-44.
8. Golubić AT, Mutvar A, Žuvić M, Huić D. The nonspecific lymph node uptake of 18F-choline in patients with prostate cancer -- a prospective observational study. Nucl Med Rev Cent East Eur. 2015;18:56-60.
9. Leiblich A, Stevens D, Sooriakumaran P. The Utility of Molecular Imaging in Prostate Cancer. Curr Urol Rep. 2016;17:26.
10. Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A et al. Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging. 2015;42:644-55.
11. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-6.
12. Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013;54:699-706.
13. Castellucci P, Picchio M. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013;40:36-40.
14. Emonds KM, Swinnen JV, Lerut E, Koole M, Mortelmans L, Mottaghy FM. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. EJNMMI Res. 2013;3:31.
15. Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011;38:1985-9.
16. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-73.
17. Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C et al. 11C-choline PET/CT in patients with hormoneresistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40:149-55.
18. Castellucci P, Ceci F, Fanti S. Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. Urol Clin North Am. 2018;45:481-7.
19. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71:630-42.
20. Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer. World J Urol. 2013;31:319-23.
21. Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55-69.
22. Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM et al. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43:1971-9.
23. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
24. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1410-7.
25. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al. PET imaging with a [68 Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-95.
26. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-40.
27. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-72.
28. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-39.
29. Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Int J Appl Radiat Isot. 1981;32:31–6.
30. Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol. 2012;2012:921674.
31. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
32. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271:220-9.
33. Larson SM, Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol. 2008;18:65-70.
34. Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L et al. 11C-choline PET/CT predicts prostate cancer–specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233- 41.
35. Giovacchini G, Incerti E, Mapelli P, Kirienko M, Briganti A, Gandaglia G et al. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2015;42:877-84.
36. Giovacchini G, Guglielmo P, Mapelli P, Incerti E, Gajate AMS, Giovannini E et al. 11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml. Eur J Nucl Med Mol Imaging. 2019;46:921-9.